Baseline characteristics
| . | MPD cohort (n = 52) . | Overall (N = 84) . |
|---|---|---|
| Age (y), median (range) | 63.0 (44-86) | 61.5 (43-86) |
| Gender, n (%) | ||
| Male | 31 (59.6) | 48 (57.1) |
| Female | 21 (40.4) | 36 (42.9) |
| ECOG Performance Status, n (%) | ||
| 0 | 25 (48.1) | 33 (39.3) |
| 1 | 23 (44.2) | 46 (54.8) |
| 2 | 4 (7.7) | 5 (6.0) |
| Heavy chain, n (%) | ||
| IgG | 29 (55.8) | 52 (61.9) |
| IgA | 13 (25.0) | 19 (22.6) |
| Time since diagnosis (y), median (range)* | 3.1 (0-16) | 3.1 (0-22) |
| Cytogenetics/FISH, n (%) | ||
| Standard risk | 40 (76.9) | 57 (67.9) |
| High risk† | 11 (21.2) | 22 (26.2) |
| Unknown | 1 (1.9) | 5 (6.0) |
| Prior lines of therapy, median (range) | 3 (1–5) | 2 (1–5) |
| Prior therapy, n (%)‡ | ||
| Corticosteroid | 50 (96.2) | 82 (97.6) |
| Bortezomib | 42 (80.8) | 65 (77.4) |
| Lenalidomide | 38 (73.1) | 59 (70.2) |
| Thalidomide | 24 (46.2) | 39 (46.4) |
| Bortezomib and lenalidomide | 31 (59.6) | 49 (58.3) |
| Bortezomib and lenalidomide or thalidomide | 38 (73.1) | 59 (70.2) |
| Alkylating agent | 37 (71.2) | 61 (72.6) |
| Anthracycline | 20 (38.5) | 29 (34.5) |
| Transplant | 29 (55.8)§ | 54 (64.3)§ |
| . | MPD cohort (n = 52) . | Overall (N = 84) . |
|---|---|---|
| Age (y), median (range) | 63.0 (44-86) | 61.5 (43-86) |
| Gender, n (%) | ||
| Male | 31 (59.6) | 48 (57.1) |
| Female | 21 (40.4) | 36 (42.9) |
| ECOG Performance Status, n (%) | ||
| 0 | 25 (48.1) | 33 (39.3) |
| 1 | 23 (44.2) | 46 (54.8) |
| 2 | 4 (7.7) | 5 (6.0) |
| Heavy chain, n (%) | ||
| IgG | 29 (55.8) | 52 (61.9) |
| IgA | 13 (25.0) | 19 (22.6) |
| Time since diagnosis (y), median (range)* | 3.1 (0-16) | 3.1 (0-22) |
| Cytogenetics/FISH, n (%) | ||
| Standard risk | 40 (76.9) | 57 (67.9) |
| High risk† | 11 (21.2) | 22 (26.2) |
| Unknown | 1 (1.9) | 5 (6.0) |
| Prior lines of therapy, median (range) | 3 (1–5) | 2 (1–5) |
| Prior therapy, n (%)‡ | ||
| Corticosteroid | 50 (96.2) | 82 (97.6) |
| Bortezomib | 42 (80.8) | 65 (77.4) |
| Lenalidomide | 38 (73.1) | 59 (70.2) |
| Thalidomide | 24 (46.2) | 39 (46.4) |
| Bortezomib and lenalidomide | 31 (59.6) | 49 (58.3) |
| Bortezomib and lenalidomide or thalidomide | 38 (73.1) | 59 (70.2) |
| Alkylating agent | 37 (71.2) | 61 (72.6) |
| Anthracycline | 20 (38.5) | 29 (34.5) |
| Transplant | 29 (55.8)§ | 54 (64.3)§ |
ECOG, Eastern Cooperative Oncology Group; IgA, immunoglobulin A; IgG, immunoglobulin G; MPD, maximum planned dose.
Data unavailable for 1 patient.
del 13 by metaphase cytogenetics or t(4;14); t(14;16), or del(17p13) by FISH.
Exposure to multiple drugs was not necessarily concurrent.
1 patient had received allogeneic transplant.